FDA Approval
Perrigo and Catalent Announce FDA Approval of Perrigo's AB-Rated Generic Version of ProAir® HFA
Perrigo
PR-M02-20-NI-041Feb 27, 2020
Finance
Perrigo Increases Its Dividend By 11%
Perrigo
PR-M04-19-NI-090Apr 30, 2019
ANDA
Perrigo Confirms Patent Challenge for Generic Version of Nascobal®
Nice Insight
PR-M03-19-NI-020Mar 07, 2019
Milestone Payment
Perrigo To Receive Milestone Payment Of $250 Million From RPI Finance Trust
Perrigo
PR-M01-19-NI-095Feb 01, 2019
Appointment
Perrigo Appoints James Dillard To Role Of Chief Scientific Officer
Perrigo
PR-M01-19-NI-044-3142Jan 16, 2019
FDA Approval
Perrigo Announces Tentative FDA Approval for the First To file Generic Version Of Ultravate® Lotion 0.05%
Perrigo
PR-M11-18-NI-107Nov 30, 2018
Launch
Perrigo Launches Its AB Rated Generic Version of Solaraze® Gel 3%
Perrigo
PR-M11-18-NI-100-3329Nov 28, 2018
Patent
Perrigo Confirms Patent Challenge For Generic Version Of Kerydin®
Perrigo
PR-M11-18-NI-008Nov 02, 2018
Financial Results
Perrigo To Release Third Quarter Calendar Year 2018 Financial Results On November 8, 2018
Perrigo
PR-M10-18-NI-097Oct 29, 2018
Growth Strategy
Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®
Perrigo
PR-M08-18-NI-117Aug 30, 2018
Business
Perrigo to Divest Its Prescription Drug Business
Nice Insight
PAO-M08-18-NI-015Aug 14, 2018
Launch
Perrigo Launches Novel Omeprazole Orally Disintegrating Tablet to Treat Frequent Heartburn
Perrigo
PR-M04-18-NI-50Apr 16, 2018
FDA
Perrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Mucinex® DM Maximum Strength Extended Release Tablets
Perrigo
PR-M03-18-NI-037-4609Mar 09, 2018
Appointment
Perrigo Appoints Ronald L. Winowiecki as Chief Financial Officer
Perrigo
PR-M02-18-NI-89Feb 23, 2018
Generics
Perrigo Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%
Perrigo
PR-M02-18-NI-90Feb 23, 2018
Acquisition
Perrigo Sells API Business to SK Capital
Nice Insight
PAO-M08-17-NI-033Aug 25, 2017